The Transformation of pathology from adenocarcinoma to squamous cell carcinoma occurs in patients of solid tumors with KRAS mutations [108], and genetic alterations in cell cycle regulators is reported, causing cell cycle dysregulation to attenuate the therapeutic response of KRAS inhibitor [117]. Here, KRAS is linked to adenocarcinoma.